Neoadjuvant chemotherapy for ovarian cancer: do we have enough evidence?

abstract - the Lancet

Comment

• References

"Although primary cytoreductive surgery followed by chemotherapy has been the standard treatment for advanced ovarian cancer for many years, neoadjuvant chemotherapy followed by interval debulking surgery has emerged as a new alternative treatment of advanced ovarian cancer after the EORTC-NCIC trial.¹ In The Lancet, Sean Kehoe and colleagues² show the benefits of using neoadjuvant chemotherapy for patients with advanced ovarian cancer. In a comparison of primary surgery versus primary chemotherapy in 552 patients with advanced ovarian cancer, they showed that primary chemotherapy was not only equally effective but also a substantially safer strategy."

 Payment Options
Purchase this article for $31.50 USD

• Online access for 24 hours